MA24571A1 - Compositions comprenant un sensibilisant a l'insuline et un secretagogue d'insuline pour une methode de traitement - Google Patents

Compositions comprenant un sensibilisant a l'insuline et un secretagogue d'insuline pour une methode de traitement

Info

Publication number
MA24571A1
MA24571A1 MA25120A MA25120A MA24571A1 MA 24571 A1 MA24571 A1 MA 24571A1 MA 25120 A MA25120 A MA 25120A MA 25120 A MA25120 A MA 25120A MA 24571 A1 MA24571 A1 MA 24571A1
Authority
MA
Morocco
Prior art keywords
insulin
compositions
treatment method
secretagogue
sensitizer
Prior art date
Application number
MA25120A
Other languages
English (en)
French (fr)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24571(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA24571A1 publication Critical patent/MA24571A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25120A 1997-06-18 1998-06-17 Compositions comprenant un sensibilisant a l'insuline et un secretagogue d'insuline pour une methode de traitement MA24571A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
MA24571A1 true MA24571A1 (fr) 1998-12-31

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25120A MA24571A1 (fr) 1997-06-18 1998-06-17 Compositions comprenant un sensibilisant a l'insuline et un secretagogue d'insuline pour une methode de traitement

Country Status (33)

Country Link
EP (3) EP1671637A3 (enEXAMPLES)
JP (1) JP2001523270A (enEXAMPLES)
KR (3) KR20070011651A (enEXAMPLES)
CN (1) CN1168451C (enEXAMPLES)
AP (1) AP1600A (enEXAMPLES)
AR (2) AR008025A1 (enEXAMPLES)
AT (1) ATE353654T1 (enEXAMPLES)
AU (1) AU8539298A (enEXAMPLES)
BG (2) BG64817B1 (enEXAMPLES)
BR (1) BR9810142A (enEXAMPLES)
CA (1) CA2294385C (enEXAMPLES)
CO (1) CO4940457A1 (enEXAMPLES)
CZ (1) CZ299310B6 (enEXAMPLES)
DE (1) DE69837089T2 (enEXAMPLES)
DZ (1) DZ2522A1 (enEXAMPLES)
EA (1) EA003025B1 (enEXAMPLES)
ES (1) ES2283064T3 (enEXAMPLES)
ID (1) ID24065A (enEXAMPLES)
IL (1) IL133137A (enEXAMPLES)
IN (1) IN189319B (enEXAMPLES)
MA (1) MA24571A1 (enEXAMPLES)
MY (1) MY125855A (enEXAMPLES)
NO (3) NO326263B1 (enEXAMPLES)
NZ (1) NZ501163A (enEXAMPLES)
OA (1) OA11510A (enEXAMPLES)
PE (1) PE108199A1 (enEXAMPLES)
PL (2) PL337510A1 (enEXAMPLES)
SK (1) SK286028B6 (enEXAMPLES)
TR (1) TR199903096T2 (enEXAMPLES)
TW (1) TW542717B (enEXAMPLES)
UA (1) UA67743C2 (enEXAMPLES)
UY (1) UY25048A1 (enEXAMPLES)
WO (1) WO1998057649A1 (enEXAMPLES)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AP1495A (en) 1999-04-23 2005-11-30 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic.
CA2389237A1 (en) 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
KR20100012105A (ko) 2003-10-31 2010-02-05 다케다 야쿠힌 고교 가부시키가이샤 인슐린 감작제, 인슐린 분비촉진제 및 폴리옥시에틸렌 소르비탄 지방산 에스테르를 함유하는 고체 제제
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL296945A1 (enEXAMPLES) 1990-07-03 1992-07-13 Yamanouchi Pharma Co Ltd
ATE116971T1 (de) 1990-08-23 1995-01-15 Pfizer Hypoglykämische hydroxyharnstoffderivate.
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
DK0579733T3 (da) 1991-04-11 2001-10-15 Upjohn Co Thiazolidindionderivater, fremstilling og anvendelse deraf
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
TW222626B (enEXAMPLES) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
RU2134686C1 (ru) 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
AR008025A1 (es) 1999-12-09
OA11510A (en) 2004-02-03
UA67743C2 (uk) 2004-07-15
TR199903096T2 (xx) 2000-08-21
DE69837089T2 (de) 2007-06-21
EP0999845A1 (en) 2000-05-17
EP2266576A1 (en) 2010-12-29
AP9901717A0 (en) 1999-12-31
PL337510A1 (en) 2000-08-28
NO2009002I1 (no) 2009-03-02
SK179199A3 (en) 2000-11-07
JP2001523270A (ja) 2001-11-20
MY125855A (en) 2006-08-30
NO20083276L (no) 2000-02-17
AR012996A1 (es) 2000-11-22
KR20080011356A (ko) 2008-02-01
NZ501163A (en) 2002-02-01
EA003025B1 (ru) 2002-12-26
PE108199A1 (es) 2000-01-14
CN1260719A (zh) 2000-07-19
BG104058A (en) 2000-10-31
BR9810142A (pt) 2000-08-08
UY25048A1 (es) 2000-09-29
ATE353654T1 (de) 2007-03-15
DZ2522A1 (fr) 2003-02-01
AP1600A (en) 2006-04-28
BG64817B1 (bg) 2006-05-31
WO1998057649A1 (en) 1998-12-23
BG109397A (bg) 2006-05-31
NO996264D0 (no) 1999-12-17
IL133137A (en) 2004-02-08
TW542717B (en) 2003-07-21
KR20070011651A (ko) 2007-01-24
ID24065A (id) 2000-07-06
HK1028200A1 (en) 2001-02-09
DE69837089D1 (de) 2007-03-29
NO326263B1 (no) 2008-10-27
PL198018B1 (pl) 2008-05-30
CZ299310B6 (cs) 2008-06-18
CN1168451C (zh) 2004-09-29
SK286028B6 (sk) 2008-01-07
NO996264L (no) 2000-02-17
CZ9904577A3 (en) 2001-05-16
CA2294385A1 (en) 1998-12-23
EP1671637A3 (en) 2007-12-19
IL133137A0 (en) 2001-03-19
EP1671637A2 (en) 2006-06-21
KR20010013840A (ko) 2001-02-26
AU8539298A (en) 1999-01-04
EP0999845B1 (en) 2007-02-14
CO4940457A1 (es) 2000-07-24
ES2283064T3 (es) 2007-10-16
EA200000039A1 (ru) 2000-08-28
IN189319B (enEXAMPLES) 2003-02-08
CA2294385C (en) 2007-06-05

Similar Documents

Publication Publication Date Title
DE69834209D1 (de) Bildverarbeitungsverfahren
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
EP0766892A4 (en) Apparatus and method for clock alignment and switching
IL135440A0 (en) Multithread data processor
FI951702L (fi) Farmaseuttinen menetelmä osteoporoosin hoitamiseksi
FI951856A7 (fi) Farmaseuttinen koostumus osteoporoosin hoitamiseksi
IL135584A0 (en) Method for treating alzheimer&#39;s disease
AU123249S (en) Developing processor for image formation
FI970300A0 (fi) Metallikelaattimerkityt peptidit
IT1268013B1 (it) Unita&#39; di sviluppo per elettrofotocopiatrici
MA24571A1 (fr) Compositions comprenant un sensibilisant a l&#39;insuline et un secretagogue d&#39;insuline pour une methode de traitement
DE69821714D1 (de) Bilderzeugungsverfahren
EP0984392A4 (en) IMAGE PROCESSOR AND IMAGE PROCESSING METHOD
KR970703005A (ko) 결상 재료의 결상 방법(improved imaging process for imaging materials)
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l&#39;insuline pour une méthode de traitement.
EP0935386A4 (en) IMAGE PROCESSOR AND INTEGRATED CIRCUIT FOR IT
FR2766044B1 (fr) Procede de traitement d&#39;une sequence d&#39;images radiologiques d&#39;un objet
DE69524127D1 (de) Flüssigentwicklerzusammensetzung
DZ2519A1 (fr) Compositions pharmaceutiques comprenant un sensibilisant à l&#39;insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.
GB9926284D0 (en) Image processor and image processing method
GB2289183B (en) White level information correction apparatus
DE69810069D1 (de) Gebührenanzeige von Faksimileübertragungen
GB9804287D0 (en) Image processing
DE69812245D1 (de) Elektrophotographisches Bildherstellungsverfahren
FR2772484B1 (fr) Procede de traitement d&#39;image d&#39;autoradiographie